Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Argenta Discovery and Dr Reddy's Laboratories have announced a major milestone in their development program targeting a novel disease-modifying approach to treat the underlying cause of certain chronic respiratory diseases including chronic obstructive pulmonary disease and severe asthma.
Subscribe to our email newsletter
Argenta CEO Dr Christopher Ashton said: “Just 18 months after signing the deal with Dr Reddy’s, the team has already selected the first candidate drug to proceed into pre-clinical development.”
“With GMP material already manufactured we are on target to enter Phase I in mid-2008 and Phase II in 2009,” he continued. “We believe we are first-in-class for this inhaled anti-inflammatory approach to treat chronic respiratory disease.”
Under the terms of a licensing agreement announced in February 2006, Argenta and Dr Reddy’s are collaborating to identify clinical candidates against an undisclosed but proven anti-inflammatory drug target and to develop these candidates to Phase II proof-of-concept.